Severity
Low
FDA Drug recall · Reported December 13, 2023
Product Mix-up: Incorrect Product Formulation
Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop recalled LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), … - a low-severity action.
LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), … was recalled by Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop in December 13, 2023. Reason: Product Mix-up: Incorrect Product Formulation. Check the official notice for the remedy. Verify recall #D-0140-2024 with the FDA Drug before acting.
The recall
Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop issued this low-severity FDA Drug recall-Product Mix-up: Incorrect Product Formulation.
Sourced from official FDA Drug enforcement records. Verify recall #D-0140-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0140-2024) was formally reported on December 13, 2023, with the manufacturer initiating the action on November 9, 2023. It is classified under Low severity (Class III), with a current status of Terminated. Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop is listed as the recalling firm, operating out of Irving, TX. Federal records list the affected scope as 190 syringes.
The documented reason for this recall is: Product Mix-up: Incorrect Product Formulation Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,322 medical devices recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
190 syringes
Related Recalls
6
0 from same agency
LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), Single-use Topical Syringe, 3mL syringe, 10/pack, Rx only, Carie Boyd Pharmaceuticals, 8400 Esters Blvd, Ste# 190, Irving, TX 75063, NDC73271-1003-1
Product Mix-up: Incorrect Product Formulation
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0140-2024 |
| Date reported | December 13, 2023 |
| Date initiated | November 9, 2023 |
| Recalling firm | Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop |
| Firm location | Irving, TX |
| Affected scope | 190 syringes |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-07-02
· 2026-06-25
· 2026-06-18
GE Medical Systems Information Technologies Inc · 2026-06-03
Medline Industries, LP · 2026-06-03
Compare this recall with Rowenta Recalls Cordless Vacuum Cleaners Due to Risk of Ser… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 13, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.